Evaluating Erythropoietin as an Indicator for Possible Kidney Injury After Cardiac Surgery

EPO: A Renal Biomarker After Cardiac Surgery

Sponsors

Lead Sponsor: University of Michigan

Source University of Michigan
Brief Summary

The purpose of the study is to evaluate kidney biomarkers and determine if there is a correlation between Erythropoietin (EPO) levels and acute kidney injury after cardiac surgery. An early biomarker for kidney injury may be helpful in identifying, monitoring and managing patients at risk for kidney failure after cardiac surgery. To evaluate Erythropoietin's role as a predictor of poor renal function in the immediate post-bypass period we plan to compare EPO levels to Neutrophil gelatinase-associated lipocalin (NGAL).

Detailed Description

Acute kidney injury (AKI) is a serious complication after cardiac surgery and cardio-pulmonary bypass. AKI is associated with high mortality.

Erythropoietin, a hormone produced by the kidneys, will be evaluated as a potential biomarker of kidney injury. Neutrophil gelatinase-associated lipocalin (NGAL) has been studied as a biomarker of kidney injury. Early kidney injury detection has been long sought and NGAL has been shown to be a promising biomarker. A troponinlike biomarker of AKI that is easily measured and capable of both early detection and risk stratification would represent an advancement in our ability to differentiate acute kidney injury from failure.

Investigating EPO as a biomarker may prove to have increased predictive value in the clinical care of cardiac surgery patients.

Overall Status Completed
Start Date November 2010
Completion Date March 2012
Primary Completion Date March 2012
Study Type Observational
Primary Outcome
Measure Time Frame
Renal injury/Failure 18 Hours after surgery
Enrollment 80
Condition
Intervention

Intervention Type: Other

Intervention Name: Cardiac Surgery

Arm Group Label: Subjects undergoing cardiac surgery

Eligibility

Sampling Method: Non-Probability Sample

Criteria:

Inclusion Criteria:

- Cardiac surgery with cardiopulmonary bypass with DHCA

- Normal renal function or renal insufficiency-serum creatinine less than 2.5 mg/dL

- Adult male and female patients 18 years and older

Exclusion Criteria:

- VADS

- Emergent cases

- Prolonged hypoxemia before, during or after bypass

- End stage renal disease

- Patients receive erythropoietin receptor agonists

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Overall Official
Last Name Role Affiliation
Yasser El Kouatli, MD Principal Investigator Department of Anesthesiology, University of Michigan
Location
Facility: University of Michigan Hospital
Location Countries

United States

Verification Date

December 2016

Responsible Party

Type: Principal Investigator

Investigator Affiliation: University of Michigan

Investigator Full Name: Yasser Kouatli

Investigator Title: Clinical Lecturer

Keywords
Has Expanded Access No
Condition Browse
Arm Group

Label: Subjects undergoing cardiac surgery

Acronym EPO
Patient Data No
Study Design Info

Observational Model: Case-Only

Time Perspective: Cross-Sectional

Source: ClinicalTrials.gov